Our Mission Statement: The Society of Biomolecular Imaging and Informatics (SBI2) is an international community of leaders, scientists, and students promoting technological advancement, discovery, and education to quantitatively interrogate biological models to provide high context information at the cellular level.
We are pleased to announce the 7th Annual High Content conference brought to you by The Society of Biomolecular Imaging and Informatics (SBI2) on September 16 and 17, 2020. This is our first Virtual Conference and we hope you will join us for a meeting that prioritizes interpersonal communications, high quality scientific presentations, and educational experiences that foster overall awareness of “up to date” techniques and the rapidly expanding strategies in imaging and informatics. This virtual meeting holds the most promise to bring to you all the outstanding features our members have come to expect from SBI2.
Registration and Poster Submissions are free this year.
This scientific event will feature 2 keynote speakers:
Lina Nilsson, Ph.D. - Senior Director of Data Science Product, Recursion Pharmaceuticals
Scott Fraser, Ph.D. - Professor of Biology, Bioengineering, & Convergent Biosciences University of Southern California.
Join our High Content 2020 Conference to:
Please click on the On demand below to see a listing of our two-day conference agenda currently available for ondemand viewing in the Auditorium.
Click on the dates to view upcoming Educational Webinars.
Lina Nilsson is Senior Director of Data Science Product at Recursion, a biotech that is reimagining drug discovery using machine learning and large-scale laboratory automation. Previously, she was the COO of Enlitic, a startup that uses deep learning to improve clinical radiology. As Innovation Director at University of California, Berkeley, she helped spin out social-impact technologies. Lina has been recognized on MIT Technology Review's "TR35" annual list of the world's top innovators. Her writings on open science, social impact technologies, and gender & tech have been published in the New York Times, Washington Post, and Science. Lina has a PhD in biomedical engineering from the ETH Zurich.
Dr. David Andrews is Director of and senior scientist in Biological Sciences at Sunnybrook Research Institute, Professor of Biochemistry and Medical Biophysics at University of Toronto and a Tier 1 Canada Research Chair in Membrane Biogenesis. His research includes, the molecular mechanisms by which Bcl-2 family proteins regulate apoptosis at mitochondria, mechanisms of protein-protein interactions, the assembly of proteins into membranes, high-content screening and development of new microscopes for fluorescence lifetime imaging microscopy.
Dr. Andrews uses fluorescence spectroscopy, fluorescence lifetime imaging and automated fluorescence microscopy to study protein-protein interactions in live cells and in membranes, protein localization in cells and the effects of drugs on cells. His lab has proposed the now widely accepted model for how Bcl-2 family proteins regulate apoptosis and has discovered and characterized small molecules that inhibit Bcl-2 family protein mediated mitochondrial outer membrane permeabilization that have applications to cancer and regenerative medicine.
Dr. Andrews is active in the public and private sector. In recent years he was president of the Society for Biomolecular Imaging and Informatics. He is a member of the editorial board of Cell Death and Differentiation. He participated in the start-up of two companies, Fermentas and Isogenica and consults for several other companies and academic centers. His group performs collaborative and contract research for a variety of biotech companies including ABBVIE, Eli Lilly, Johnson and Johnson, Novartis and Celgene. He holds licensed patents in areas such as translational regulation, in vitro evolution, peptide display technologies and optical microscopy.
Mark joined NIBR in 2016 as data scientist specializing in machine learning applied to high-content microscopy. He completed a Ph.D. in biomedical engineering at Vanderbilt University, a postdoctoral fellowship at Harvard University, followed by a staff scientist position in the Imaging Platform at the Broad Institute in Cambridge MA.
Dr. Harrill works as a cellular and molecular toxicologist with the US Environmental Protection Agency's Center for Computational Toxicology and Exposure. Dr. Harrill’s expertise is in vitro toxicology, specifically the application of next generation sequencing, high content imaging (HCI) and other complementary technologies for high-throughput chemical hazard screening, characterization and risk assessment. Dr. Harrill is currently a lead investigator for NCCT’s high-throughput transcriptomics and high-throughput phenotypic profiling hazard screening programs that focus on the use of broad-based high-content profiling assays for concentration-response screening of environmental chemicals in human-derived in vitro test systems. Dr. Harrill received his B.S. in Biochemistry from North Carolina State University and a Ph.D. in Toxicology for the University of North Carolina at Chapel Hill. Dr. Harrill’s graduate and postdoctoral training focused on the application of transcriptomic technologies for evaluating mechanisms of pesticide neurotoxicity and development of HCI-based high-/medium-throughput methods for in vitro developmental neurotoxicity screening. Dr. Harrill then served as a principal investigator at a non-profit research institute researching the role of ligand-activated nuclear receptors in tissue development and liver carcinogenesis using transcriptomic technologies as well as developing novel in vitro models for assessing chemical effects on hepatic stem/progenitor cells. Dr. Harrill also has experience from the private sector in conducting human health risk assessments using USEPA and state-level guidance as well as devising and managing rapid-phase environmental sampling, analysis and data interpretation programs during events involving the release of potentially hazardous chemicals.
Dr. Fuhui Long is a Staff Analytics Engineer at Cytiva, a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. Her work over the years mainly focuses on developing machine learning, deep learning, and image analysis algorithms and software to help address challenging problems in biomedical applications and life sciences. Currently at Cytiva, she is leading the development of deep learning methods to segment nuclei, cells, and other organelles for the high content analysis software INCarta. Before joining Cytiva, she was with GE Healthcare briefly, working on the same topic. She worked as a senior machine learning R&D engineer at Allen Institute for Brain Science and a research scientist at Howard Hughes Medical Institute, where she developed very useful computational techniques for microscopy image analysis to help address questions in brain research and published high impact papers in Nature, Science, and Cell.
Arvonn Tully is a Senior Software Application Specialist at Yokowaga Life Innovations. He has more than 15 years of experience working in 3D image analysis, with a special interest in sub cellular tracking, neuronal reconstruction, and finding solutions for complex analysis problems. Prior to joining Yokogawa, Arvonn worked for Arivis to solve problems with terabyte sized images and image analysis in VR collaboration. At Bitplane, he provided extensive training in 3d Image analysis for users and developing novel 3d co-localization solutions. His research background was focused on imaging and biophysics of large dense core vesicles in Drosophila at the University of Pittsburgh.
Judi Wardwell is a Senior Application Scientist at InSphero and President Elect of the SBI2 board of directors. She has more than 25 years of experience working in the pharma industry and has a keen interest in evolving imaging technologies and applications that help drive drug discovery. Prior to joining InSphero, Judi was a Principal Investigator in a functional genomics group at Bristol-Myers Squibb, where her team conducted phenotypic screens in physiologically-relevant cell models with a focus on the identification of new drug targets. Prior to BMS, she held scientific research positions at Wyeth and Hoffmann-La Roche. Judi is also the author of a book chapter and several journal articles on high content imaging-related topics such as HCS data management, analysis of multiparametric imaging data, and 3D imaging/analysis of multicellular spheroids.
Thermo Fisher Scientific is the world leader in serving science, our mission is to enable our customers to make the world healthier, cleaner and safer. High-content screening/analysis (HCS) was invented by and registered as a trademark of Cellomics, which is now part of Thermo ...See more See less
PerkinElmer is working closely with laboratories around the world to deliver the nucleic acid isolation, automation, real-time PCR, antibody testing, and NGS library preparation solutions they need to rapidly respond to the SARS-CoV-2 challenges both today and tomorrow. To ...See more See less
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic ...See more See less
Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community - and through that, we aim to accelerate access to better health for people everywhere.
You need to conduct assay development or drug screening for cancer research using biologically relevant cell models. Molecular Devices complete imaging solutions can help you achieve your goals. Our imaging cytometry platform offers visual confidence and cell-by-cell statistics ...See more See less
At Olympus, we are focused on improving people's lives every day. We do this through innovation. As a precision technology leader, we design and deliver innovative solutions in our core business areas: Medical and Surgical Products, Life Science Imaging Systems, Industrial ...See more See less
ExpressCells leverages proprietary gene-editing tools and the power of CRISPR to create custom, knock-in cell lines for drug discovery, toxicology, and other biologic research.
Genedata combines computational, scientific, and technical expertise with extensive biopharma R&D domain knowledge to deliver user-friendly solutions that are scalable, open, and aligned with industry processes.
BioStatus invents, develops and manufactures novel reagents for cell-based imaging, cytometry and screening applications. The company manufactures all products in the UK and supplies customers and distributors worldwide. BioStatus operates to the ISO 9001:2015 quality standard.
The Society of Biomolecular Imaging and Informatics (SBI2) is an international community of leaders, scientists, and students promoting technological advancement, discovery, and education to quantitatively interrogate biological models to provide high context information at the ...See more See less
Core Life Analytics empowers life scientists by giving them access to powerful yet easy to use web-based data analytics tools, that allow them to, rapidly and independently, mine their high content and high throughput data. Our products help them to leverage the power of cloud ...See more See less
Chroma Technology Corp. manufactures optical interference filters for a wide range of imaging and detection applications. We are proud to be 100% employee-owned and an active and caring member of the communities we serve and in which we live.
Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. Formerly part of GE Healthcare Life Sciences, we have a rich heritage tracing back hundreds of years, and a fresh beginning since 2020. Our ...See more See less
At SLAS, we provide a wide array of relevant education, information, innovation and access to the world's largest network of professionals focused on leveraging technology for scientific advancement.
Yokogawa's high-content analysis systems (HCA), also known as high-content screening systems (HCS), address a range of research applications from basic science to drug discovery screening. Paired with our advanced analysis software, our HCA systems provide high quality 3D ...See more See less
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events
Research And Development
Social Media Promotions5%
WAVE Newsletter Promotion3%
Labroots Registration (Also interested in)1%
Trending Newsletter Promotion1%
Medical Laboratory Technician4%
Clinical Laboratory Scientist1%
Life Science Company5%
Contract Research Organization (Cro)1%